Ken Griffin Immunovant, Inc. Transaction History

Citadel Advisors LLC

$483 Billion
Q2 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Immunovant, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 74,400 shares of IMVT stock, worth $2.05 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

74,400

Previous 80,300 7.35%

Holding current value

$2.05 Million

Previous $2.59 Million 24.29%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$25.1 - $31.61 $2.89 Million - $3.64 Million	115,013 Added 50.33%	343,512 $9.07 Million
Q1 2024 May 15, 2024	SELL	$30.27 - $43.79 $17.6 Million - $25.5 Million	-582,940 Reduced 71.84%	228,499 $7.38 Million
Q4 2023 Feb 14, 2024	SELL	$31.31 - $44.19 $1.06 Million - $1.5 Million	-33,937 Reduced 4.01%	811,439 $34.2 Million
Q3 2023 Nov 14, 2023	BUY	$18.55 - $39.96 $10 Million - $21.6 Million	539,527 Added 176.4%	845,376 $32.5 Million
Q2 2023 Aug 14, 2023	SELL	$14.2 - $23.75 $12.2 Million - $20.4 Million	-860,027 Reduced 73.77%	305,849 $5.8 Million
Q1 2023 May 15, 2023	BUY	$15.27 - $19.72 $2.95 Million - $3.81 Million	193,154 Added 19.86%	1,165,876 $18.1 Million
Q4 2022 Feb 14, 2023	BUY	$6.59 - $17.75 $5.94 Million - $16 Million	901,589 Added 1267.47%	972,722 $17.3 Million
Q3 2022 Nov 14, 2022	SELL	$3.93 - $6.37 $152,766 - $247,614	-38,872 Reduced 35.34%	71,133 $397,000
Q2 2022 Aug 15, 2022	SELL	$3.38 - $5.65 $387,300 - $647,410	-114,586 Reduced 51.02%	110,005 $429,000
Q1 2022 May 16, 2022	SELL	$5.06 - $8.77 $117,240 - $203,200	-23,170 Reduced 9.35%	224,591 $1.24 Million
Q4 2021 Feb 14, 2022	BUY	$7.33 - $9.32 $579,201 - $736,447	79,018 Added 46.83%	247,761 $2.11 Million
Q3 2021 Nov 15, 2021	SELL	$7.01 - $11.37 $46,749 - $75,826	-6,669 Reduced 3.8%	168,743 $1.47 Million
Q2 2021 Aug 16, 2021	SELL	$9.4 - $16.85 $3.62 Million - $6.49 Million	-384,929 Reduced 68.7%	175,412 $1.85 Million
Q1 2021 May 17, 2021	SELL	$13.08 - $49.6 $2.73 Million - $10.4 Million	-208,693 Reduced 27.14%	560,341 $8.99 Million
Q4 2020 Feb 16, 2021	BUY	$36.36 - $52.71 $2.47 Million - $3.58 Million	67,959 Added 9.69%	769,034 $35.5 Million
Q3 2020 Nov 16, 2020	BUY	$22.61 - $38.9 $11 Million - $19 Million	487,423 Added 228.14%	701,075 $24.7 Million
Q2 2020 Aug 14, 2020	BUY	$13.87 - $28.44 $2.72 Million - $5.57 Million	195,896 Added 1103.27%	213,652 $5.2 Million
Q1 2020 May 15, 2020	BUY	$8.36 - $17.13 $148,440 - $304,160	17,756 New	17,756 $276,000

Others Institutions Holding IMVT

# of Institutions

220

Shares Held

65.1M

Call Options Held

697K

Put Options Held

629K

View Full List

About Immunovant, Inc.

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

More about IMVT

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account